| P2093 | author name string | Jodi R Heins | |
| | Debra K Farver | |
| | Dennis D Hedge | |
| | Joe D Strain | |
| P2860 | cites work | Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe | Q58924160 |
| | Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin | Q59567863 |
| | Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea | Q63859728 |
| | Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy | Q67957024 |
| | Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial | Q68882288 |
| | Susceptibility of Clostridium difficile to metronidazole, its bioactive metabolites and tinidazole | Q69421608 |
| | Susceptibility of Clostridium difficile to LY146032 | Q70182328 |
| | Randomized controlled trial of colestipol in antibiotic-associated colitis | Q70224304 |
| | Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile | Q70646834 |
| | In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile | Q71432978 |
| | Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group | Q72751375 |
| | The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii | Q73118857 |
| | Binding of Clostridium difficile toxin A to human milk secretory component | Q77465305 |
| | The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile | Q79757063 |
| | Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea | Q79895613 |
| | Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea | Q80052797 |
| | Probiotics for Clostridium difficile diarrhea: putting it into perspective | Q80535616 |
| | Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile | Q80536283 |
| | The outcome of surgery in fulminant Clostridium difficile colitis | Q82259380 |
| | In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis | Q83346158 |
| | Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland | Q21128674 |
| | Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters | Q24563857 |
| | Probiotic use in clinical practice: what are the risks? | Q28245049 |
| | A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease | Q28254686 |
| | Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial | Q29394639 |
| | Update on Clostridium difficile associated disease | Q30442246 |
| | Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. | Q33211234 |
| | Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole | Q33214954 |
| | Nitazoxanide for the treatment of Clostridium difficile colitis | Q33250018 |
| | Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide | Q33276804 |
| | The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study | Q33432290 |
| | Neutralizing activity against Clostridium difficile toxin in the supernatants of cultured colostral cells | Q33906618 |
| | Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube | Q33964412 |
| | GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis | Q33982760 |
| | Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec | Q33990521 |
| | Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults | Q34006013 |
| | Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin | Q34108924 |
| | In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp | Q34141027 |
| | In vitro activity of OPT-80 against Clostridium difficile | Q34142125 |
| | Clostridium difficile--Associated diarrhea: A review | Q34185015 |
| | Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea | Q34389970 |
| | Ramoplanin: a lipoglycodepsipeptide antibiotic | Q34405651 |
| | An epidemic, toxin gene-variant strain of Clostridium difficile | Q34472146 |
| | In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species | Q34509301 |
| | Saccharomyces cerevisiae fungemia: an emerging infectious disease | Q34557580 |
| | Tinidazole: a nitroimidazole antiprotozoal agent | Q34565233 |
| | Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent | Q34593188 |
| | Clostridium difficile: changing epidemiology and new treatment options | Q34645735 |
| | Recurrent Clostridium difficile-associated colitis responding to cholestyramine | Q34694764 |
| | Treatment of Clostridium difficile infection. | Q51894323 |
| | Fucoidin prevents Clostridium difficile toxin-A-induced ileal enteritis in mice. | Q52581850 |
| | Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. | Q53756939 |
| | Fucidic acid use in metronidazole nonresponders with Clostridium difficile infection. | Q55044292 |
| | Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A | Q34714718 |
| | Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins | Q34718134 |
| | Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin | Q34880915 |
| | Development potential of rifalazil | Q35056073 |
| | Safety of probiotics that contain lactobacilli or bifidobacteria | Q35081764 |
| | In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria | Q35103522 |
| | Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. | Q35122389 |
| | Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. | Q35131944 |
| | Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine | Q35353994 |
| | Factors associated with failure of metronidazole in Clostridium difficile-associated disease | Q35752327 |
| | Clostridium difficile-associated diarrhea in adults | Q35828291 |
| | Intravenous immunoglobulin therapy for severe Clostridium difficile colitis | Q35841034 |
| | Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity | Q35874779 |
| | In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004 | Q35912682 |
| | Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice | Q35913487 |
| | Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections | Q36140657 |
| | Treatment of Clostridium difficile-associated disease: old therapies and new strategies | Q36240849 |
| | Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea | Q36416873 |
| | Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea | Q36457609 |
| | An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease | Q36552629 |
| | Emergence of Clostridium difficile-associated disease in North America and Europe. | Q36590739 |
| | Emerging therapies in the treatment of Clostridium difficile-associated disease | Q36659957 |
| | Past, present, and future therapies for Clostridium difficile-associated disease | Q36674768 |
| | Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties | Q36700782 |
| | Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic | Q36747339 |
| | Clostridium difficile-associated disease: changing epidemiology and implications for management | Q36757577 |
| | Epidemiology, pathogenesis, and management of Clostridium difficile infection | Q36778849 |
| | Hypervirulent strains of Clostridium difficile | Q36815464 |
| | Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii | Q36862309 |
| | Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate | Q36965686 |
| | Clinical recognition and diagnosis of Clostridium difficile infection | Q37051294 |
| | Recent advances in Clostridium difficile-associated disease. | Q37077926 |
| | Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. | Q38470026 |
| | In vitro and in vivo activities of nitazoxanide against Clostridium difficile | Q39474787 |
| | In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates | Q39730584 |
| | Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters | Q40233154 |
| | Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea | Q40288784 |
| | Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. | Q40438125 |
| | Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis | Q40445495 |
| | Clostridium difficile colitis: an efficient clinical approach to diagnosis | Q40677572 |
| | Clostridium difficile colitis | Q40679117 |
| | Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee | Q41468617 |
| | Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin | Q41890836 |
| | Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain | Q42012422 |
| | Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses | Q42410111 |
| | In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes | Q42549999 |
| | Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea | Q43006167 |
| | Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients | Q43354697 |
| | Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin | Q43627285 |
| | Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. | Q43772396 |
| | Multiple relapses of Clostridium difficile-associated diarrhea responding to an extended course of cholestyramine | Q44673987 |
| | Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea | Q44836632 |
| | A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea | Q44911083 |
| | Rifampin and pseudomembranous colitis | Q44994714 |
| | Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea | Q46376143 |
| | Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada | Q46486664 |
| | Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection | Q46688405 |
| | Intravenous immunoglobulin for resistant Clostridium difficile infection | Q46816696 |
| | Measures to control and prevent Clostridium difficile infection | Q46821792 |
| | Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea | Q46843245 |
| | Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea | Q46844928 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | Clostridium difficile | Q310543 |
| P304 | page(s) | 949-964 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | New advances in the treatment of Clostridium difficile infection (CDI) | |
| P478 | volume | 4 | |